Novozymes A/S - NVZMY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$61.17
▲ +2.34 (3.98%)

This chart shows the closing price for NVZMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novozymes A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVZMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVZMY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Novozymes A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $61.17.

This chart shows the closing price for NVZMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Novozymes A/S. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2023UBS GroupUpgradeSell ➝ Neutral
10/30/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
10/10/2023DNB MarketsUpgradeHold ➝ Buy
2/20/2023Credit Suisse GroupUpgradeUnderperform ➝ Neutral
12/16/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
12/13/2022BarclaysDowngradeOverweight ➝ Equal Weight
12/13/2022DNB MarketsUpgradeSell ➝ Hold
12/7/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/10/2022Exane BNP ParibasDowngradeNeutral ➝ Underperform370.00
10/10/2022BNP ParibasDowngradeNeutral ➝ Underperform
9/14/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
4/29/2022Kepler Capital MarketsUpgradeReduce ➝ Hold
4/27/2022Nordea Equity ResearchUpgradeSell ➝ Hold
3/30/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
3/17/2022BarclaysLower Target510.00 ➝ 490.00
2/4/2022Credit Suisse GroupLower TargetUnderperform ➝ Underperform390.00 ➝ 360.00
10/29/2021CitigroupReiterated RatingNeutral
10/28/2021UBS GroupReiterated RatingSell
9/2/2021BarclaysReiterated RatingOverweight
8/23/2021Berenberg BankUpgradeHold ➝ Buy
8/16/2021Credit Suisse GroupReiterated RatingUnderperform
8/13/2021UBS GroupReiterated RatingSell
7/28/2021BarclaysReiterated RatingOverweight
7/14/2021UBS GroupReiterated RatingSell
5/10/2021BarclaysReiterated RatingOverweight
5/4/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/30/2021Berenberg BankReiterated RatingHold
4/28/2021UBS GroupReiterated RatingSell
4/28/2021Credit Suisse GroupReiterated RatingUnderperform
4/28/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
2/9/2021BarclaysReiterated RatingOverweight
2/3/2021Berenberg BankUpgradeSell ➝ Hold
1/26/2021DanskeUpgradeSell ➝ Hold
1/25/2021BarclaysUpgradeUnderweight ➝ Overweight
11/18/2020BarclaysReiterated RatingUnderweight
10/8/2020Berenberg BankDowngradeHold ➝ Sell
10/1/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
8/13/2020BarclaysReiterated RatingUnderweight
7/28/2020BarclaysInitiated CoverageUnderweight
7/8/2020UBS GroupReiterated RatingSell
7/2/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
5/12/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell
1/14/2020BNP ParibasDowngradeOutperform ➝ Neutral
1/7/2020The Goldman Sachs GroupInitiated CoverageBuy
12/17/2019Berenberg BankDowngradeBuy ➝ Hold
11/20/2019CitigroupUpgradeNeutral ➝ Buy
9/30/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
8/19/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
(Data available from 6/19/2019 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Novozymes A/S logo
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $61.17
Low: $60.70
High: $61.27

50 Day Range

MA: $58.90
Low: $54.21
High: $63.54

52 Week Range

Now: $61.17
Low: $38.75
High: $63.89

Volume

19,078 shs

Average Volume

9,370 shs

Market Capitalization

$28.65 billion

P/E Ratio

38.72

Dividend Yield

0.97%

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Novozymes A/S?

The following Wall Street research analysts have issued research reports on Novozymes A/S in the last year: Deutsche Bank Aktiengesellschaft, DNB Markets, and UBS Group AG.
View the latest analyst ratings for NVZMY.

What is the current price target for Novozymes A/S?

0 Wall Street analysts have set twelve-month price targets for Novozymes A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Novozymes A/S in the next year.
View the latest price targets for NVZMY.

What is the current consensus analyst rating for Novozymes A/S?

Novozymes A/S currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NVZMY.

What other companies compete with Novozymes A/S?

Other companies that are similar to Novozymes A/S include Gilead Sciences, Moderna, Biogen, argenx and BioNTech. Learn More about companies similar to Novozymes A/S.

How do I contact Novozymes A/S's investor relations team?

Novozymes A/S's physical mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company's listed phone number is (454) 446-0000 and its investor relations email address is [email protected]. The official website for Novozymes A/S is www.novozymes.com. Learn More about contacing Novozymes A/S investor relations.